Found: 11
Select item for more details and to access through your institution.
Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 8, p. N.PAG, doi. 10.1007/s11095-020-02882-0
- By:
- Publication type:
- Article
Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1381, doi. 10.1111/dom.13664
- By:
- Publication type:
- Article
Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 2, p. 413, doi. 10.1111/bcp.13812
- By:
- Publication type:
- Article
Empirical Bayes models for multiple probe type microarrays at the probe level.
- Published in:
- BMC Bioinformatics, 2008, v. 9, p. 1, doi. 10.1186/1471-2105-9-156
- By:
- Publication type:
- Article
From Plan to Pivot: How Model‐Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 653, doi. 10.1002/cpt.3362
- By:
- Publication type:
- Article
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 15, p. 1, doi. 10.1161/JAHA.123.034067
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 11, p. 1, doi. 10.1161/JAHA.123.033985
- By:
- Publication type:
- Article
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 2, p. 255, doi. 10.1007/s40262-023-01337-0
- By:
- Publication type:
- Article
Population Pharmacodynamic Dose–Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 4, p. 551, doi. 10.1007/s40262-024-01360-9
- By:
- Publication type:
- Article
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article